Aha1 is a member of the Hsp90 cochaperone family, and is thought to stimulate Hsp90 ATPase activity by
competing with p23 and other co-chaperones for
Hsp90 binding (1, 2). It may affect a step in the
endoplasmic reticulum to Golgi trafficking. Aha1 also
interacts with HSPCA/Hsp90 and with the cytoplasmic
tail of the vesicular stomatistis virus glycoproteins
(VSV G) (3). Aha1 is expressed in numerous tissues,
including the brain, heart, skeletal muscle, and
kidney, and at low levels, the liver and placenta. Aha1
might be a potential therapeutic strategy to increase
sensitivity to HSP inhibitors (4).